Uma Sinha - Net Worth and Insider Trading

Uma Sinha Net Worth

The estimated net worth of Uma Sinha is at least $38 Million dollars as of 2024-11-05. Uma Sinha is the Chief Scientific Officer of Eidos Therapeutics Inc and owns about 306,525 shares of Eidos Therapeutics Inc (EIDX) stock worth over $37 Million. Uma Sinha is also the Chief Scientific Officer of BridgeBio Pharma Inc and owns about 14,000 shares of BridgeBio Pharma Inc (BBIO) stock worth over $348,180. Details can be seen in Uma Sinha's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Uma Sinha has not made any transactions after 2021-01-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Uma Sinha

Uma Sinha Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Uma Sinha owns 4 companies in total, including Eidos Therapeutics Inc (EIDX) , BridgeBio Pharma Inc (BBIO) , and Social Capital Suvretta Holdings Corp III (DNAC) among others .

Click here to see the complete history of Uma Sinha’s form 4 insider trades.

Insider Ownership Summary of Uma Sinha

Ticker	Comapny	Transaction Date	Type of Owner
EIDX	Eidos Therapeutics Inc	2021-01-13	director & Chief Scientific Officer
BBIO	BridgeBio Pharma Inc	2019-07-01	Chief Scientific Officer
DNAC	Social Capital Suvretta Holdings Corp III	2022-07-11	director
		2022-07-11	director

Uma Sinha Latest Holdings Summary

Uma Sinha currently owns a total of 2 stocks. Among these stocks, Uma Sinha owns 306,525 shares of Eidos Therapeutics Inc (EIDX) as of January 13, 2021, with a value of $37 Million and a weighting of 99.08%. Uma Sinha also owns 14,000 shares of BridgeBio Pharma Inc (BBIO) as of July 1, 2019, with a value of $348,180 and a weighting of 0.92%.

Latest Holdings of Uma Sinha

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
EIDX	Eidos Therapeutics Inc	2021-01-13	306,525	122.21	37,460,420
BBIO	BridgeBio Pharma Inc	2019-07-01	14,000	24.87	348,180

Holding Weightings of Uma Sinha

Uma Sinha Form 4 Trading Tracker

According to the SEC Form 4 filings, Uma Sinha has made a total of 5 transactions in Eidos Therapeutics Inc (EIDX) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Eidos Therapeutics Inc is the sale of 10,000 shares on January 13, 2021, which brought Uma Sinha around $1 Million.

According to the SEC Form 4 filings, Uma Sinha has made a total of 0 transactions in BridgeBio Pharma Inc (BBIO) over the past 5 years. The most-recent trade in BridgeBio Pharma Inc is the acquisition of 14,000 shares on July 1, 2019, which cost Uma Sinha around $238,000.

Insider Trading History of Uma Sinha

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Uma Sinha Trading Performance

GuruFocus tracks the stock performance after each of Uma Sinha's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Uma Sinha is -23.64%. GuruFocus also compares Uma Sinha's trading performance to market benchmark return within the same time period. The performance of stocks bought by Uma Sinha within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Uma Sinha's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Uma Sinha

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	8.48
Relative Return to S&P 500(%)	8.84

Uma Sinha Ownership Network

Ownership Network List of Uma Sinha

No Data

Ownership Network Relation of Uma Sinha

Uma Sinha Owned Company Details

What does Eidos Therapeutics Inc do?

Who are the key executives at Eidos Therapeutics Inc?

Uma Sinha is the director & Chief Scientific Officer of Eidos Therapeutics Inc. Other key executives at Eidos Therapeutics Inc include Senior Vice President & Finance Franco Valle , Chief Business Officer Cameron Turtle , and See Remarks Jonathan C Fox .

Eidos Therapeutics Inc (EIDX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eidos Therapeutics Inc (EIDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eidos Therapeutics Inc (EIDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eidos Therapeutics Inc (EIDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eidos Therapeutics Inc Insider Transactions

No Available Data

What does BridgeBio Pharma Inc do?

Who are the key executives at BridgeBio Pharma Inc?

Uma Sinha is the Chief Scientific Officer of BridgeBio Pharma Inc. Other key executives at BridgeBio Pharma Inc include 10 percent owner Kkr Genetic Disorder L.p. , director & See Remarks Neil Kumar , and See Remarks Brian C Stephenson .

BridgeBio Pharma Inc (BBIO) Insider Trades Summary

Over the past 18 months, Uma Sinha made no insider transaction in BridgeBio Pharma Inc (BBIO). Other recent insider transactions involving BridgeBio Pharma Inc (BBIO) include a net sale of 12,000 shares made by Randal W Scott , a net sale of 182,045 shares made by Neil Kumar , and a net sale of 73,947 shares made by Brian C Stephenson .

In summary, during the past 3 months, insiders sold 5,831,544 shares of BridgeBio Pharma Inc (BBIO) in total and bought 0 shares, with a net sale of 5,831,544 shares. During the past 18 months, 7,676,737 shares of BridgeBio Pharma Inc (BBIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 7,676,737 shares.

BridgeBio Pharma Inc (BBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

BridgeBio Pharma Inc Insider Transactions

No Available Data

What does Social Capital Suvretta Holdings Corp III do?

Who are the key executives at Social Capital Suvretta Holdings Corp III?

Uma Sinha is the director of Social Capital Suvretta Holdings Corp III. Other key executives at Social Capital Suvretta Holdings Corp III include 10 percent owner Control Empresarial De Capitales S.a. De C.v. , 10 percent owner Sc Pipe Holdings Llc , and 10 percent owner Tolerantia, Llc .

Social Capital Suvretta Holdings Corp III (DNAC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Social Capital Suvretta Holdings Corp III (DNAC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Social Capital Suvretta Holdings Corp III (DNAC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Social Capital Suvretta Holdings Corp III (DNAC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Social Capital Suvretta Holdings Corp III Insider Transactions

No Available Data

What does ProKidney Corp do?

Who are the key executives at ProKidney Corp?

Uma Sinha is the director of ProKidney Corp. Other key executives at ProKidney Corp include SVP of Regulatory Development Darin J. Weber , director & 10 percent owner Pablo G. Legorreta , and 10 percent owner Control Empresarial De Capitales S.a. De C.v. .

ProKidney Corp (PROK) Insider Trades Summary

Over the past 18 months, Uma Sinha made no insider transaction in ProKidney Corp (PROK). Other recent insider transactions involving ProKidney Corp (PROK) include a net sale of 13,273,000 shares made by Chamath Palihapitiya , a net sale of 170,593 shares made by Darin J. Weber , and a net purchase of 8,441,462 shares made by Control Empresarial De Capitales S.a. De C.v. .

In summary, during the past 3 months, insiders sold 16,412 shares of ProKidney Corp (PROK) in total and bought 0 shares, with a net sale of 16,412 shares. During the past 18 months, 13,443,593 shares of ProKidney Corp (PROK) were sold and 31,059,371 shares were bought by its insiders, resulting in a net purchase of 17,615,778 shares.

ProKidney Corp (PROK)'s detailed insider trading history can be found in Insider Trading Tracker table.

ProKidney Corp Insider Transactions

No Available Data

Uma Sinha Mailing Address

Above is the net worth, insider trading, and ownership report for Uma Sinha. You might contact Uma Sinha via mailing address: C/o Eidos Therapeutics, Inc., 101 Montgomery Street, Suite 2550, San Francisco Ca 94101.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.